Clinical trial No longer in our active list Phase 3 Interventional Ages 18 and up

Evaluating zipalertinib with chemotherapy for advanced lung cancer

Official title: Randomized, Controlled, Open-label, Phase 3, Global Multi - Center Trial to Assess the Efficacy and Safety of Zipalertinib Plus Chemotherapy Versus Chemotherapy Alone, in Patients With Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

Run by Taiho Oncology, Inc. · NCT05973773 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is testing if adding a new drug called zipalertinib to standard chemotherapy can help people with advanced lung cancer that has specific genetic mutations feel better and live longer.

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment272 (estimated)
SponsorTaiho Oncology, Inc.
Industry-sponsored
Drugs / interventionsamivantamab, gefitinib, erlotinib, afatinib, dacomitinib, osimertinib, mobocertinib, sunvozertinib, furmonertinib, poziotinib, Zipalertinib, radiation, chemotherapy
Locations114 sites (Henderson, Nevada and 113 other locations)
Trial IDNCT05973773 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 and older with pathologically confirmed advanced or metastatic nonsquamous NSCLC and specific EGFR exon 20 insertion mutations who have not received prior systemic treatment.

Probably not a fit

Patients with early-stage NSCLC or those who have received prior systemic treatment for their advanced disease may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the safety and efficacy of zipalertinib when combined with standard first-line platinum-based chemotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC) that has specific EGFR exon 20 insertion mutations. It consists of two parts: a safety lead-in to determine the optimal dose of zipalertinib, followed by a randomized Phase 3 trial comparing the combination treatment to chemotherapy alone. Patients who progress on chemotherapy may have the option to receive zipalertinib as a monotherapy. The study will be conducted across multiple sites in Nevada.

Why it matters

Potential benefit: If successful, this treatment could provide a new effective option for patients with a specific mutation in advanced lung cancer.

How similar studies have gone: While this approach is novel for this specific mutation, similar studies have shown promise in targeting other mutations in lung cancer.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion-

1. Provide written informed consent.
2. ≥18 years of age (or meets the country's regulatory definition for legal adult age, whichever is greater).
3. Pathologically confirmed, locally advanced or metastatic nonsquamous NSCLC
4. Has not received any prior systemic treatment for their locally advanced or metastatic nonsquamous NSCLC. Prior adjuvant/neoadjuvant treatment received \>6 months prior to first dose of study treatment is allowed for early-stage

   NSCLC. Prior monotherapy with an approved EGFR TKI (ie, gefitinib, erlotinib, afatinib, dacomitinib, or osimertinib) as nonstandard first-line therapy for the treatment of locally advanced or metastatic disease is allowed if all of the following criteria are met:
   1. Treatment duration did not exceed 8 weeks;
   2. Lack of disease response was documented (radiographically) by an increase in tumor burden (a copy of the computerized tomography \[CT\] report showing increase in tumor burden from baseline should be submitted);
   3. Associated toxicities have resolved to baseline; and
   4. The EGFR TKI was discontinued at least 2 weeks or 4 half-lives prior to randomization, whichever is longer.

   Prior therapy with EGFR TKI agents targeting exon20ins mutations including amivantamab, mobocertinib, sunvozertinib, furmonertinib, and poziotinib is not allowed.
5. Documented EGFR mutation status, as determined by local testing performed at a CLIA certified (US) or accredited (outside of the US) local laboratory, defined as follows:

   1. Part A: EGFR ex20ins or other uncommon single or compound EGFR mutation
   2. Part B: EGFR ex20ins mutation
6. Archival tumor tissue available for submission, with minimum quantity sufficient to evaluate EGFR mutation status and, where possible, other biomarkers. Patients with insufficient tissue (details provided in laboratory manual) may be eligible following discussion with the sponsor; a fresh biopsy will not be required.
7. Patients with brain metastasis(es) who have previously received definitive local treatment and have stable central nervous system (CNS) disease (defined as being neurologically stable and off corticosteroid for at least 2 weeks prior to enrollment) are eligible. If brain metastases are diagnosed on screening imaging, the patient may be rescreened for eligibility after definitive treatment.

   b. Asymptomatic brain metastases ≤2 cm in size can be eligible for inclusion if, in the opinion of the Investigator, immediate definitive treatment is not indicated.
8. At least one measurable lesion as determined per RECIST 1.1 for patients enrolling to Part B. Patients enrolling to Part A may be enrolled without measurable disease.
9. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
10. Adequate organ function, as defined by the laboratory value
11. Have a life expectancy of at least 3 months as assessed by the investigator.
12. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test prior to administration of the first dose of study treatment. Female patients are not considered to be of childbearing potential if they are postmenopausal (no menses for 12 months without an alternative medical cause) or permanently sterile (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).
13. Both males and females of reproductive potential must agree to use effective birth control during the study prior to the first dose and for 6 months after the last dose of study treatment or longer, based on local requirements.

Exclusion -

1. Is currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged not to be scientifically or medically compatible with this study.
2. Prior treatment with any of the following within the specific time frame specified:

   1. Zipalertinib (TAS6417/CLN-081) at any time.
   2. Thoracic radiotherapy ≤28 days, palliative radiation of nonthoracic disease ≤14 days, or palliative radiation of a single lesion ≤7 days prior to first dose of study treatment.
   3. Major surgery (excluding placement of vascular access) ≤28 days prior to first dose of study treatment.
   4. All prescribed medication, over-the-counter medication, vitamin preparations and other food supplements, or herbal medications that are strong or moderate CYP3A4 inducers or inhibitors within 7 days prior to first dose.
3. Have any unresolved toxicity of Grade ≥2 from previous anticancer treatment in the neoadjuvant or adjuvant setting, except for Grade 2 alopecia or skin pigmentation. Patients with other chronic but stable Grade 2 toxicities may be allowed to enroll after agreement between the investigator and Sponsor.
4. Past medical history of interstitial lung disease, treatment-related pneumonitis (any grade), or any evidence of clinically active interstitial lung disease.
5. Impaired cardiac function or clinically significant cardiac disease, including any of the following:

   1. History of congestive heart failure (CHF) Class III/IV according to the New York Heart Association (NYHA) Functional Classification .
   2. Serious cardiac arrhythmias requiring treatment.
   3. Resting corrected QT interval (QTc) \>470 msec calculated using Fridericia's formula (QTcF).
6. Unable to swallow tablets or has any disease or condition that may significantly affect gastrointestinal (GI) absorption of zipalertinib (such as inflammatory bowel disease, malabsorption syndrome, or prior GI resection).
7. History of another primary malignancy ≤2 years prior to the date of first dose of study treatment unless at least one of the following criteria are met:

   1. Adequately treated basal or squamous cell carcinoma of the skin
   2. Cancer of the breast or cervix in situ
   3. Previously treated malignancy, if all treatment for that malignancy was completed at least 2 years prior to first dose of study treatment, and no current evidence of disease
   4. Concurrent malignancy determined to be clinically stable and not requiring tumor directed treatment
8. Known history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) that is unstable or not controlled with treatment.
9. History of COVID-19 infection within 4 weeks prior to enrolment and/or have persistent, clinically significant pulmonary symptoms related to prior COVID-19 infection.
10. Active bleeding disorders.
11. Known hypersensitivity to the ingredients in zipalertinib or any drugs similar in structure or class. To platinum-containing drugs (ie, cisplatin, carboplatin), pemetrexed, or any known excipients of these drugs. b. Contraindications toning drugs (ie, cisplatin, carboplatin) or pemetrexed according to the respective local labels.
12. History of leptomeningeal disease and spinal cord compression.
13. Is unable or unwilling to take dexamethasone, folic acid, and/or vitamin B12 supplementation during treatment with pemetrexed.
14. Is pregnant or lactating or planning to become pregnant
15. The patient is, in the investigator's opinion, unable or unwilling to comply with the trial procedures.

Where it's running

  • Comprehensive Cancer Centers of Nevada - Henderson
    Henderson, Nevada, United States
    Recruiting
  • Comprehensive Cancer Centers of Nevada - Horizon Ridge Henderson
    Henderson, Nevada, United States
    Recruiting
  • Comprehensive Cancer Centers of Nevada - Southeast Henderson - Stephanie
    Henderson, Nevada, United States
    Recruiting
  • Comprehensive Cancer Centers of Nevada - Summerlin Medical Center II
    Las Vegas, Nevada, United States
    Recruiting
  • Comprehensive Cancer Centers of Nevada - Southwest
    Las Vegas, Nevada, United States
    Recruiting
  • Comprehensive Cancer Centers of Nevada - Central Valley - Twain
    Las Vegas, Nevada, United States
    Recruiting
Show 44 more locations
  • Comprehensive Cancer Centers of Nevada - Northwest
    Las Vegas, Nevada, United States
    Recruiting
  • Gabrail Cancer and Research Center
    Canton, Ohio, United States
    Recruiting
  • University of Texas MD Anderson Cancer Center
    Houston, Texas, United States
    Recruiting
  • Universitair Ziekenhuis Leuven - Campus Gasthuisberg
    Leuven, Flemish Brabant, Belgium
    Recruiting
  • Algemeen Ziekenhuis Maria Middelares
    Gent, Oost-Vlaaderen, Belgium
    Recruiting
  • Algemeen Ziekenhuis Delta - Campus Menen
    Menen, West Flanders, Belgium
    Recruiting
  • Algemeen Ziekenhuis Delta - Campus Rumbeke
    Rosières, West-Vlaanderen, Belgium
    Recruiting
  • Centro Regional Integrado de Oncologia
    Fortaleza, Ceará, Brazil
    Recruiting
  • Hospital São Lucas da PUCRS
    Porto Alegre, Rio Grande Do Sul, Brazil
    Recruiting
  • Clínica Neoplasias Litoral
    Itajaí, Santa Catatina, Brazil
    Recruiting
  • Hospital Amaral Carvalho
    Jaú, São Paulo, Brazil
    Recruiting
  • Multi-profile Hospital for Active Treatment Uni Hospital
    Panagyurishte, Pazardzhik, Bulgaria
    Recruiting
  • University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna-ISUL
    Sofia, Bulgaria
    Recruiting
  • William Osler Health System - Brampton Civic Hospital
    Brampton, Ontario, Canada
    Recruiting
  • Les Hôpitaux Universitaires de Strasbourg
    Strasbourg cedex, Alsace, France
    Recruiting
  • Hôpital Côte De Nacre
    Caen cedex 9, Basse-Normandie, France
    Recruiting
  • Institut Curie
    Paris cedex, Ile-de-France, France
    Recruiting
  • Centre Hospitalier Universitaire Limoges
    Limoges, Limousin, France
    Recruiting
  • Hôpital Haut-Lévêque
    Pessac, Nouvelle-Aquitaine, France
    Recruiting
  • Centre Hospitalier Le Mans
    Le Mans cedex 9, Pays De La Loire, France
    Recruiting
  • Gustave Roussy
    Villejuif, Val-de-Marne, France
    Recruiting
  • Hôpital Ambroise-Paré
    Boulogne-Billancourt, Île-de-France, France
    Recruiting
  • Asklepios Klinik Altona
    Hamburg, Hamburg (Hansestadt), Germany
    Recruiting
  • Universitätsklinikum Gießen und Marburg - Gießen
    Gießen, Hessen, Germany
    Recruiting
  • Universitätsklinikum Regensburg
    Regensburg, Germany
    Recruiting
  • General Hospital for Thoracic Diseases Sotiria
    Athens, Attica, Greece
    Recruiting
  • Metropolitan General
    Piraeus, Attica, Greece
    Recruiting
  • University General Hospital of Patras
    Patra, Peloponnese, Greece
    Recruiting
  • Metropolitan Hospital
    Peiraias, Pireas, Greece
    Recruiting
  • University General Hospital of Larissa
    Larissa, Thessaly, Greece
    Recruiting
  • BioClinic Thessaloniki
    Thessaloniki, Greece
    Recruiting
  • Emek Medical Center
    Afula, Israel
    Recruiting
  • Shaare Zedek Medical Center
    Jerusalem, Israel
    Recruiting
  • Hadassah University Hospital Ein Kerem
    Jerusalem, Israel
    Recruiting
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, Israel
    Recruiting
  • Assuta Hospital - Ramat HaHayal
    Tel aviv, Israel
    Recruiting
  • Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST
    Meldola, Forlì-Cesena, Italy
    Recruiting
  • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele
    Milan, Italy
    Recruiting
  • Azienda Ospedaliero - Universitaria di Modena
    Modena, Italy
    Recruiting
  • Fondazione IRCCS Policlinico San Matteo
    Pavia, Italy
    Recruiting
  • Azienda Unità Sanitaria Locale della Romagna
    Ravenna, Italy
    Recruiting
  • Azienda Ospedaliera Universitaria Integrata Verona
    Verona, Italy
    Recruiting
  • Aichi Cancer Center
    Nagoya, Aiti [Aichi], Japan
    Recruiting
  • Hirosaki University Hospital
    Hirosaki-Shi, Aomori, Japan
    Recruiting

+64 more sites. See ClinicalTrials.gov for the full list.

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • Zipalertinib vs placebo after surgery for uncommon EGFR-mutant NSCLC

    This study tests whether zipalertinib can help people with early-stage, surgically removed NSCLC that has uncommon EGFR mutations-by comparing it to placebo.

    Recruiting at 108 sites Phase 3 Taiho Oncology, Inc. · Anchorage, Alaska and 252 other locations · NCT07128199

  • Evaluating zipalertinib for advanced lung cancer with specific EGFR mutations

    This study is testing a new drug called zipalertinib to see if it can help people with advanced lung cancer that has specific genetic mutations and who have few other treatment options.

    Recruiting at 69 sites Phase 2 Taiho Oncology, Inc. · Birmingham, Alabama and 79 other locations · NCT05967689

  • Amivantamab with platinum chemotherapy for metastatic EGFR‑mutant non‑small cell lung cancer

    This study will try giving amivantamab together with platinum chemotherapy to adults with metastatic NSCLC who have specific EGFR mutations to see how long their cancer stays controlled and how safe the treatment is.

    Recruiting at 11 sites Groupe Francais De Pneumo-Cancerologie · Aix-en-Provence and 15 other locations · NCT07563205

  • BEBT-109 treatment for lung cancer with specific mutations

    This study is testing a new drug called BEBT-109 to see if it can help people with a specific type of lung cancer that has certain mutations, especially those who haven't had much success with other treatments.

    Recruiting at 2 sites Phase 2 BeBetter Med Inc · Guangzhou, Guangdong and 1 other locations · NCT06706713

  • Understanding resistance to amivantamab in lung cancer patients

    This study is trying to understand why some lung cancer patients with a specific mutation stop responding to the drug amivantamab, by looking at their blood and tumor samples after their disease gets worse.

    Recruiting at 10 sites Groupe Francais De Pneumo-Cancerologie · Bordeaux and 17 other locations · NCT06247826

  • Assessing furmonertinib for lung cancer patients with specific mutations after surgery

    This study is testing if a new drug called furmonertinib can help lung cancer patients with specific mutations stay cancer-free after their surgery.

    Recruiting Phase 2 Sichuan Cancer Hospital and Research Institute · Chengdu, Sichuan · NCT06192849

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.